Patent intelligence · US
US 2016213609
OPHTHALMIC SUSPENSION COMPOSITION
OPHTHALMIC SUSPENSION COMPOSITION
Patent details — US 2016213609
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 28, 2016
- Expiration
- Jul 23, 2036
- Applicant
- BAUSCH & LOMB [US]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 56 A I, A61K 31/ 573 A I
Quick answer
US 2016213609 (OPHTHALMIC SUSPENSION COMPOSITION) is held by BAUSCH & LOMB [US]. Status: granted. Granted Jul 28, 2016. Expires Jul 23, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAUSCH & LOMB [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 56 A I, A61K 31/ 573 A I, A61K 47/ 02 A I, A61K 47/ 06 A I
More from BAUSCH & LOMB [US]
Related pharmaceutical patents in our USPTO index.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 2019151500
OPHTHALMIC VISCOELASTIC COMPOSITIONS
granted -
CA 3043000
DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE
granted -
US 2015038439
METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS
granted -
US 2014206764
Poly(Nitrogen/Amine) Derivatives of a Natural Wax and Ophthalmic Compositions
granted -
US 2014142182
Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
granted
Frequently asked questions
What is US patent 2016213609?
US 2016213609 (OPHTHALMIC SUSPENSION COMPOSITION) is held by BAUSCH & LOMB [US]. Status: granted. Granted Jul 28, 2016. Expires Jul 23, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2016213609?
BAUSCH & LOMB [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2016213609 expire?
Our index shows an expiration date of Jul 23, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.